Live Breaking News & Updates on Christopherk Murray

Stay updated with breaking news from Christopherk murray. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Blueprint Medicines (NASDAQ:BPMC) Raised to "Market Perform" at Leerink Partnrs

Blueprint Medicines (NASDAQ:BPMC) Raised to "Market Perform" at Leerink Partnrs
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United States , Christopherk Murray , Piper Sandler , Leerink Partnrs , Securities Exchange Commission , Blueprint Medicines Corporation , Needham Company , Polar Capital Holdings Plc , Norges Bank , Blueprint Medicines , Free Report , Get Free Report , Exchange Commission , Capital Holdings Plc , Springs Capital Management , Partners Management , Medicines Corporation , Blueprint Medicines Daily ,

Blueprint Medicines (NASDAQ:BPMC) Price Target Increased to $76.00 by Analysts at Citigroup

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective hoisted by Citigroup from $65.00 to $76.00 in a report issued on Friday, Benzinga reports. They currently have a sell rating on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus upped their price objective on […] ....

United States , Kate Haviland , Stifel Nicolaus , Christopherk Murray , Securities Exchange Commission , Financial Services Group Inc , Mirae Asset Global Investments Co , Associates Corp , Blueprint Medicines Corporation , Principal Financial Group Inc , Blueprint Medicines , Free Report , Moderate Buy , Medicines Trading Down , Get Free Report , Exchange Commission , Asset Global Investments , Financial Group , Services Group , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc , Boost Price Target , Citigroup Inc ,

Blueprint Medicines (NASDAQ:BPMC) Given New $104.00 Price Target at Piper Sandler

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price target lifted by Piper Sandler from $78.00 to $104.00 in a research note published on Friday, Benzinga reports. Piper Sandler currently has a neutral rating on the biotechnology company’s stock. Several other research firms also recently commented on BPMC. Wedbush reiterated an outperform rating and issued […] ....

United States , Christopherk Murray , Piper Sandler , Needham Company , Securities Exchange Commission , American Century Companies Inc , Rafferty Asset Management , Blueprint Medicines Company Profile , China Universal Asset Management Co , Blueprint Medicines Corporation , Blueprint Medicines , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Asset Management , Century Companies , Universal Asset Management , Medicines Corporation , Blueprint Medicines Daily ,